Nordic countries share similar working life structures and basis for working hour regulations. The overall aim of the project is to develop evidence-based models and solutions related to working hours to support health, well-being and work participation among employees in the Nordic countries.
The Nordic Centre for Security Technologies and Societal Values will advance research, education and training, industrial strategy and public policy in support of a wider and deeper understanding of the security technology/values interface.
NORDRESS, the Nordic Centre of Excellence on Resilience and Societal Security, is a network of scientists and emergency management experts who join forces to increase societal resilience to natural hazards.
Crohn's disease is a chronic inflammatory bowel disease. The biological drug Remicade is used in patients with Crohn's disease when normal treatment is inadequate. About one in three of the patients starting treatment with Remicade have sustained good effect over several years. However, serious side effects such as; infections, allergic reactions and concerns about long-term safety, with suspected increased risk of developing cancer, necessitate exploring strategies for when and in which patients to stop (discontinue) treatment again.
The Committee of Nordic ART and Safety (CoNARTaS) was established five year ago and have the responsibility for the Nordic ART and Safety database including all children born after assisted reproductive technology (ART) in Finland, Norway, Sweden and Denmark since 1982.
The NORD-STAR clinical trial will provide extremely valuable information on the treatment of early rheumatoid arthritis. The study aims to find out, which is the most effective treatment strategy in early rheumatoid arthritis. As the first trial ever it will compare four different treatment modalities head-to-head.
Acute myelogenous leukemia (AML) is the most coomon acute leukemia in adults with and annual incidence of 4 cases per 100 000 inhabitans. Median age at diagnosis is 70 years. For patients below 55 years, the prognosis has gradually improved the last decades, but elderly patiens still do poorly; the survival being around 30% with no improvement of outome after standard chemotherapy treatment.